Raphael Frey is leading the team for Early Development Services for Bioconjugates at Lonza in Visp, Switzerland. His team offers solutions for preclinical bioconjugate drug development, combining state-of-the art technologies and Lonza’s extensive expertise in bioconjugate manufacturing. Raphael studied organic chemistry at the Swiss Federal Institute of Technology (ETH Zurich) and earned his Ph.D. in chemical biology, focusing on enzyme engineering and biocatalysis.
ADC Review, Journal of Antibody-drug Conjugates (ISSN 2327-0152) is an international peer-reviewed publication designed to serve the needs of a diverse community of individuals including academia, life sciences, pharma, research, clinicians and physicians. Along with regulatory affairs, we also cover government authorities and representatives from payers to policymakers.